Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoURANIA: Utidelone + Cisplatin in Neoadjuvant Breast Cancer
NCT06510465Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2024
- Primary completion
- Mar 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in breast cancer, sponsored by Renji Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06510465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510465.